Microflora changes with the use of a vaginal microbicide

被引:31
作者
Clarke, JG
Peipert, JF
Hillier, SL
Heber, W
Boardman, L
Moench, TR
Mayer, K
机构
[1] Brown Univ, Women & Infants Hosp, Div Res, Sch Med,Dept Obstet & Gynecol, Providence, RI 02905 USA
[2] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA
[3] ReProtect LLC, Baltimore, MD USA
[4] Brown Univ, Miriam Hosp, Sch Med, Dept Internal Med, Providence, RI USA
[5] Fenway Community Hlth, Boston, MA USA
关键词
D O I
10.1097/00007435-200205000-00007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The rate of HIV transmission is increasing more in women than in any other group. There is an urgent need for the development of microbicides with activity against this virus that women can use during intercourse. These products must be convenient, effective, and safe, and ideally they will cause minimal disruption in the normal vaginal ecosystem. Goal: The objective of this study was to evaluate changes in vaginal microflora, specifically Lactobacillus species, with the use of BufferGel. Study Design: A prospective cohort study was performed to evaluate the change in vaginal flora before and after BufferGel use. BufferGel was applied vaginally once or twice daily for 14 days by low-risk abstinent and monogamous women. Results: There was no change in frequency of Lactobacillus species after BufferGel use. However, there was a decrease in H2O2-producing lactobacilli (from 4.9 x 10(7) to 1.1 x 10(7) cfu. P = 0.001). The proportion of facultative gram-negative rods present increased from 27% to 65% after BufferGel use, whereas obligately anaerobic microbes decreased from 62% to 38%. Conclusion: Use of BufferGel once or twice daily for 14 days resulted in no clinically significant change in Lactobacillus colonization.
引用
收藏
页码:288 / 293
页数:6
相关论文
共 35 条
[1]  
ACHILLES S, 1997, INT C SEX TRANSM DIS
[2]  
Anderson DJ, 1998, AIDS RES HUM RETROV, V14, pS43
[3]   Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent [J].
Balzarini, J ;
Naesens, L ;
Verbeken, E ;
Laga, M ;
Van Damme, L ;
Parniak, M ;
Van Mellaert, L ;
Anné, J ;
De Clercq, E .
AIDS, 1998, 12 (10) :1129-1138
[4]  
*BF GOODR CO, 1994, B BF GOODR CO
[5]   COMPARATIVE-STUDY OF INACTIVATION OF HERPES-SIMPLEX VIRUS TYPE-1 AND TYPE-2 BY COMMONLY USED ANTISEPTIC AGENTS [J].
CROUGHAN, WS ;
BEHBEHANI, AM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (02) :213-215
[6]   The effectiveness of condoms in reducing heterosexual transmission of HIV [J].
Davis, KR ;
Weller, SC .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (06) :272-279
[7]   CHALLENGES FOR THE DEVELOPMENT OF FEMALE-CONTROLLED VAGINAL MICROBICIDES [J].
ELIAS, CJ ;
HEISE, LL .
AIDS, 1994, 8 (01) :1-9
[8]   From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection [J].
Fleming, DT ;
Wasserheit, JN .
SEXUALLY TRANSMITTED INFECTIONS, 1999, 75 (01) :3-17
[9]  
GRAVES S, 1980, BRIT J VENER DIS, V56, P269
[10]   Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections [J].
Hawes, SE ;
Hillier, SL ;
Benedetti, J ;
Stevens, CE ;
Koutsky, LA ;
WolnerHanssen, P ;
Holmes, KK .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :1058-1063